Patent · US Active

Combination therapy for treating malignancies

US10695352B2 · kind B2 · utility

4Cited by

13References

15Claims

0Family size

Assignees

CELGENE CORPORATION · US
Agios Pharmaceuticals, Inc. · US

Inventors

Vivek Saroj Kumar Chopra · South San Francisco, US
Jorge DiMartino · Belmont, US
Laurie A. Kenvin · New Hope, US
Robert Douglas Knight · Berkeley Heights, US
Kyle MacBeth · Boston, US
Krishnan Viswanadhan · East Hanover, US
Qiang Xu · Cupertino, US
Samuel V. Agresta · Lexington, US

Key dates

Filing date	Oct 14, 2016
Grant date	Jun 30, 2020
Priority date	—
Expiry date	Oct 14, 2036

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2300/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are methods and compositions for treating cancers in patients carrying an IDH2 mutation using a combination of an inhibitor of a mutant IDH2 enzyme and a DNA demethylating agent.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.